LONDON (Alliance News) - Hutchison China Meditech Ltd said Thursday it commenced a phase I study of HMPL-523 to treat elderly patients with acute myeloid leukemia in China.
The aim of the study is to evaluate the safety, pharmacokinetics and preliminary efficacy of the combination between the company's novel spleen tyrosine kinase inhibitor and azacitidine, an approved nucleoside metabolic inhibitor.
The primary outcome measures are overall response rate and adverse events, the biopharmaceutical company added.
Acute myeloid leukemia is a a cancer of blood and bone marrow characterized by rapid disease progression.
Hutchison China Meditech shares were trading up 1.1% at 4,550.00 pence each.
Hutchmed (HCM)